Abstract CT077: Potential utility of minimal residual disease (MRD) to identify relapse in pediatric and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients treated with tisagenlecleucel
Year: 2019
Type: conference-abstract
Source: Clinical Trials
Authors: Michael A. Pulsipher, Xia Han, Máire Quigley, Gabor Kari, Susana Rives, Theodore W. Laetsch, Gary D. Myers, Hidefumi Hiramatsu, Gregory A. Yanik, Muna Qayed, Timothy Driscoll, Michael W. Boyer, Heather Stefanski, Jochen Buchner, Andre Baruchel, Peter Bader, Lan Yi, Creton Kalfoglou, Harlan Robins, Erik Yusko, Gullu Gorgun, Eric Bleickardt, Stephane Wong, Stephan A. Grupp
Institutions: University of Southern California, Children's Hospital of Los Angeles, The University of Texas Southwestern Medical Center, Children's Mercy Hospital, Kyoto University, C. S. Mott Children's Hospital, Emory University, Duke Medical Center, University of Utah, University of Minnesota, Oslo University Hospital, Assistance Publique – Hôpitaux de Paris, Hôpital Robert-Debré, University Hospital Frankfurt, Fred Hutch Cancer Center, Adaptive Biotechnologies (United States), Children's Hospital of Philadelphia
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2955383189